The present invention relates to a compound represented by Formula (I): ##STR00001##
wherein -L- is C(X), or the like, Z is NR.sup.5, or the like, Z.sup.A is NR.sup.5A, or the like, W is C(R.sup.8R.sup.9)n-, W.sup.A is C(R.sup.3R.sup.4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R.sup.2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

The present invention relates to a compound represented by Formula (I): ##STR00001##
wherein -L- is C(X), or the like, Z is NR.sup.5, or the like, Z.sup.A is NR.sup.5A, or the like, W is C(R.sup.8R.sup.9)n-, W.sup.A is C(R.sup.3R.sup.4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R.sup.2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, ##STR00001## Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, ##STR00001## Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I:

##STR00001## or a co-crystal, solvate, salt or combination thereof.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I:

##STR00001## or a co-crystal, solvate, salt or combination thereof.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##

Described herein are substituted indazoles comprising formula (II) that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. Formula (II) may link to detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. ##STR00001##

Described herein are substituted indazoles comprising formula (II) that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. Formula (II) may link to detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. ##STR00001##